Navigation Links
Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Date:1/31/2008

in Ann Arbor, Michigan, and the Mayo Clinic in Rochester, Minnesota.

The trial (REO 014) is a Phase II, open-label, single agent study whose primary objective is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity of intravenous, multiple dose REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN(R) is delivered intravenously to patients at a dose of 3x10(10) TCID(50) for five consecutive days. Patients may receive additional five-day cycles of therapy every four weeks for a maximum of eight cycles. Up to 52 patients will be enrolled in the study.

Eligible patients must have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the

meaning of Section 21E of the Securities Exchange Act of 1934, as

amended. Forward-looking statements, including the Company's expectations

related to the U.S. Phase II sarcoma clinical trial and the Company's

belief as to the potential of REOLYSIN(R) as a cancer therapeutic,

involve known and unknown risks and uncertainties, which could cause the

Company's ac
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
3. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
6. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
7. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
10. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
11. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 WIRB-Copernicus Group ® ... and ethical review services for clinical research, announced ... a division of Richmond, VA ... biosafety and biosecurity consulting firm in ... WCG,s biosafety division – WCG Biosafety™ – will ...
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
(Date:7/24/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property ... intellectual property, today announced that the Company will issue ... 2014 on Monday, August 18, 2014 for shareholders. Management ... on Monday, August 18, 2014 to discuss the company,s ... CEO, Anthony Hayes . Following prepared ...
(Date:7/24/2014)... As part of the long-term strategic ... MENA region during 2014 with potential global expansion. , ... with DZS to manage our clinical trials globally and ... of R&D and President of SBI pharmaceuticals MENA, Dr. ... with a focus on utilizing eClinical software and flexible ...
Breaking Biology Technology:WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... New Haven, Conn.A team led by Yale University scientists ... different cells in the blood using magnetizable liquids. The ... 7 in the online edition of the Proceedings ... improve the speed and sensitivity of tests used to ...
... quickly produce ultra-lightweight, bendable batteries and supercapacitors in ... a sheet of paper with ink made of ... conductive storage device, said Yi Cui, assistant professor ... needs a low-cost, high-performance energy storage device, such ...
... , QUINCY, Mass., ... International), a leading biotech developer and manufacturer of renewable biochemicals, ... to receive up to $50 million for its planned biobased ... integrated biorefinery projects that won funding or loan guarantees, Myriant ...
Cached Biology Technology:New technology could boost disease detection tests' speed and sensitivity 2Dip ordinary paper into ink infused with nanotubes and nanowires to create an instant battery 2Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2
(Date:7/25/2014)... 25, 2014 Biometrics industry expands ... to digital technology for online & commerce payments while ... (NASDAQ: GOOG ), LifeLock Inc. (NYSE: ... ), Apple Inc. (NASDAQ: AAPL ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:7/24/2014)... NEW YORK, NY (July 24, 2014) Scientists ... Research Institute are one step closer to creating ... from a patient,s own cells. , For ... stem (iPS) cells lines from skin samples of ... they developed an accelerated protocol to induce these ...
(Date:7/24/2014)... ply silent freeways, solar panels blanket rooftops and power ... howling winds and from the blazing desert sun. , ... and economically feasible to convert California,s all-purpose energy infrastructure ... Energy , the plan shows the way to ... that could create tens of thousands of jobs and ...
Breaking Biology News(10 mins):Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... most promising technological research projects at University System of ... cash to help them through the most difficult phase ... With $5.1 million in federal funding, the Maryland ... research institutions and the U.S. Army Research Laboratory (ARL), ...
... one way when crammed together like sardines in a can. ... seat is empty and they have more personal space. Scientists ... involved in health and disease inside living cells. The cover ... (C&EN), ACS, weekly newsmagazine, focuses on how the study of ...
... Rensselaer Polytechnic Institute Professor Georges Belfort has ... of separations processes in biochemical engineering. Belfort, ... Engineering at Rensselaer, in recent weeks received the ... of Biological Products from the American Chemical Society ...
Cached Biology News:$5.1 million Army-Md. alliance speeds university research to market 2$5.1 million Army-Md. alliance speeds university research to market 3$5.1 million Army-Md. alliance speeds university research to market 4$5.1 million Army-Md. alliance speeds university research to market 5Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award 2
... LVF-HL, LVF-CUVADPT, FHS-LVF, and the CVD-Diffuse ... Linear Variable Filters to create the world's ... wavelength and adjustable bandpass. Each filter features ... band (99.8%). These filters -- with ...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Request Info...
MW5...
Biology Products: